Skip header and navigation

Narrow By

45 records – page 1 of 3.

Erythropoiesis-stimulating agent (ESA) therapy and chronic kidney disease (CKD)

https://libcat.nshealth.ca/en/permalink/chpams35406
Nova Scotia Health Authority. Renal Program. Halifax, NS: Nova Scotia Health Authority , 2023.
Pamphlet Number
1493
Available Online
View Pamphlet
Erythropoiesis-stimulating agents (ESAs) are a group of medications that help take the place of a hormone called erythropoietin (EPO). People with chronic kidney disease (CKD) may not have enough EPO coming from their kidneys to tell their body to make more red blood cells. This pamphlet explains how to take and store this medication, and lists possible side effects.
Available Online
View Pamphlet
Corporate Author
Nova Scotia Health Authority. Renal Program
Place of Publication
Halifax, NS
Publisher
Nova Scotia Health Authority
Date of Publication
2023
Format
Pamphlet
Language
English
Physical Description
1 electronic document ([4] p.) : digital, PDF file
Subjects (MeSH)
Renal insufficiency, chronic - complications
Anemia - drug therapy
Subjects (LCSH)
Chronic renal failure--Complications
Renal anemia
Abstract
Erythropoiesis-stimulating agents (ESAs) are a group of medications that help take the place of a hormone called erythropoietin (EPO). People with chronic kidney disease (CKD) may not have enough EPO coming from their kidneys to tell their body to make more red blood cells. This pamphlet explains how to take and store this medication, and lists possible side effects.
Responsibility
Prepared by: Renal Program
Pamphlet Number
1493
Less detail

One-Alpha® (alfacalcidol) and hemodialysis

https://libcat.nshealth.ca/en/permalink/chpams36672
Nova Scotia Health Authority. Pharmacy Services, Nova Scotia Health Authority. Renal Program. Halifax, NS: Nova Scotia Health Authority , 2023.
Pamphlet Number
1470
Available Online
View Pamphlet
One-Alpha® is a medication with the active ingredient alfacalcidol. This is a form of vitamin D. The liver changes alfacalcidol to calcitriol, which is a form of vitamin D that can be used by the body. Alfacalcidol helps your body control your calcium and phosphate levels. Calcium and phosphate are needed to build healthy bones. People get vitamin D from sunlight, and from eating oily fish and milk products. People with kidney disease cannot change enough vitamin D into calcitriol. This can ca…
Available Online
View Pamphlet
Corporate Author
Nova Scotia Health Authority. Pharmacy Services
Nova Scotia Health Authority. Renal Program
Place of Publication
Halifax, NS
Publisher
Nova Scotia Health Authority
Date of Publication
2023
Format
Pamphlet
Language
English
Physical Description
1 electronic document ([4] p.) : digital, PDF file
Subjects (MeSH)
Renal Insufficiency, Chronic - drug therapy
Renal Dialysis
Subjects (LCSH)
Chronic renal failure
Kidneys--Diseases--Treatment
Hemodialysis
Abstract
One-Alpha® is a medication with the active ingredient alfacalcidol. This is a form of vitamin D. The liver changes alfacalcidol to calcitriol, which is a form of vitamin D that can be used by the body. Alfacalcidol helps your body control your calcium and phosphate levels. Calcium and phosphate are needed to build healthy bones. People get vitamin D from sunlight, and from eating oily fish and milk products. People with kidney disease cannot change enough vitamin D into calcitriol. This can cause low calcium levels of in the blood and weaker bones. One-Alpha® raises the amount of vitamin D in your body that can be used. How to take the medication, side effects to watch for, and how to store it are reviewed. One-Alpha® is a brand name for alfacalcidol.
Responsibility
Prepared by: Renal Pharmacy Team, Renal Program
Pamphlet Number
1470
Less detail

Lanthanum (Fosrenol) and chronic kidney disease (CKD)

https://libcat.nshealth.ca/en/permalink/chpams35370
Nova Scotia Health Authority. Renal Program. Halifax, NS: Nova Scotia Health Authority , 2023.
Pamphlet Number
1466
Available Online
View Pamphlet
Lanthanum (LAN-tha-num) is a medication used to lower the amount of phosphorus (a mineral that builds strong bones and teeth) in your blood. Lanthanum binds (attaches) to the phosphorus in the foods you eat and stops your body from taking it in. A person with chronic kidney disease (CKD) is less able to remove phosphorus from their body. When there is too much phosphorus in your blood, it pushes calcium out of your bones. This makes your bones weaker. Hemodialysis can remove some of the extra …
Available Online
View Pamphlet
Corporate Author
Nova Scotia Health Authority. Renal Program
Place of Publication
Halifax, NS
Publisher
Nova Scotia Health Authority
Date of Publication
2023
Format
Pamphlet
Language
English
Physical Description
1 electronic document ([4] p.) : digital, PDF file
Subjects (MeSH)
Renal Insufficiency, Chronic - drug therapy
Renal Dialysis
Lanthanum
Subjects (LCSH)
Chronic renal failure
Kidneys--Diseases--Treatment
Hemodialysis
Abstract
Lanthanum (LAN-tha-num) is a medication used to lower the amount of phosphorus (a mineral that builds strong bones and teeth) in your blood. Lanthanum binds (attaches) to the phosphorus in the foods you eat and stops your body from taking it in. A person with chronic kidney disease (CKD) is less able to remove phosphorus from their body. When there is too much phosphorus in your blood, it pushes calcium out of your bones. This makes your bones weaker. Hemodialysis can remove some of the extra phosphorus, but you may need a medication like lanthanam to remove more. Fosrenol® is the brand name for lanthanum. This pamphlet explains how to take lanthanum, possible side effects, and how to store this medication.
Notes
Previous title: Fosrenol (Lanthanum) and hemodialysis
Responsibility
Prepared by: Renal Program
Pamphlet Number
1466
Less detail

Sevelamer (Renagel) and chronic kidney disease (CKD)

https://libcat.nshealth.ca/en/permalink/chpams35372
Nova Scotia Health Authority. Renal Program. Halifax, NS: Nova Scotia Health Authority , 2023.
Pamphlet Number
1464
Available Online
View Pamphlet
Sevelamer (se-VEL-a-mer) is a medication that lowers the amount of phosphorus (a mineral that builds strong bones and teeth) in your blood. Sevelamer binds (attaches) to the phosphorus in the foods you eat and stops your body from taking it in. A person with chronic kidney disease (CKD) is less able to remove phosphorus from their body. When there is too much phosphorus in your blood, it pushes calcium out of your bones. This makes your bones weaker. Hemodialysis can remove some of the extra ph…
Available Online
View Pamphlet
Corporate Author
Nova Scotia Health Authority. Renal Program
Place of Publication
Halifax, NS
Publisher
Nova Scotia Health Authority
Date of Publication
2023
Format
Pamphlet
Language
English
Physical Description
1 electronic document ([4] p.) : digital, PDF file
Subjects (MeSH)
Sevelamer
Renal Insufficiency, Chronic - drug therapy
Renal Dialysis
Subjects (LCSH)
Hemodialysis
Chronic renal failure
Kidneys--Diseases--Treatment
Abstract
Sevelamer (se-VEL-a-mer) is a medication that lowers the amount of phosphorus (a mineral that builds strong bones and teeth) in your blood. Sevelamer binds (attaches) to the phosphorus in the foods you eat and stops your body from taking it in. A person with chronic kidney disease (CKD) is less able to remove phosphorus from their body. When there is too much phosphorus in your blood, it pushes calcium out of your bones. This makes your bones weaker. Hemodialysis can remove some of the extra phosphorus, but you may need a medication like sevelamer to remove more. Renagel® is one brand name for sevelamer. This pamphlet explains how to take sevelamer, possible side effects, and how to store this medication.
Notes
Previous title: Renagel (Sevelamer) and Hemodialysis
Responsibility
Prepared by: Renal Program
Pamphlet Number
1464
Less detail

Rocaltrol® (calcitriol) and hemodialysis

https://libcat.nshealth.ca/en/permalink/chpams36671
Nova Scotia Health Authority. Pharmacy Services, Nova Scotia Health Authority. Renal Program. Halifax, NS: Nova Scotia Health Authority , 2023.
Pamphlet Number
1468
Available Online
View Pamphlet
Rocaltrol® is a medication with the active ingredient calcitriol. This is a form of vitamin D that can be used by the body. Calcitriol helps your body control your calcium and phosphate levels. Calcium and phosphate are needed to build healthy bones. People get vitamin D from sunlight, and from eating oily fish and milk products. People with kidney disease cannot change enough vitamin D into calcitriol. This can cause low calcium levels in the blood and weaker bones. Rocaltrol raises the amoun…
Available Online
View Pamphlet
Corporate Author
Nova Scotia Health Authority. Pharmacy Services
Nova Scotia Health Authority. Renal Program
Place of Publication
Halifax, NS
Publisher
Nova Scotia Health Authority
Date of Publication
2023
Format
Pamphlet
Language
English
Physical Description
1 electronic document ([4] p.) : digital, PDF file
Subjects (MeSH)
Renal Insufficiency, Chronic - drug therapy
Renal Dialysis
Calcitriol
Subjects (LCSH)
Chronic renal failure
Kidneys--Diseases--Treatment
Hemodialysis
Abstract
Rocaltrol® is a medication with the active ingredient calcitriol. This is a form of vitamin D that can be used by the body. Calcitriol helps your body control your calcium and phosphate levels. Calcium and phosphate are needed to build healthy bones. People get vitamin D from sunlight, and from eating oily fish and milk products. People with kidney disease cannot change enough vitamin D into calcitriol. This can cause low calcium levels in the blood and weaker bones. Rocaltrol raises the amount of vitamin D in your body that can be used. How to take the medication, side effects to watch for, and how to store it are reviewed. Rocaltrol® is a brand name for calcitriol.
Responsibility
Prepared by: Renal Pharmacy Team, Renal Program
Pamphlet Number
1468
Less detail

Oral irons and chronic kidney disease (CKD)

https://libcat.nshealth.ca/en/permalink/chpams35375
Nova Scotia Health Authority. Renal Program. Halifax, NS: Nova Scotia Health Authority , 2023.
Pamphlet Number
1469
Available Online
View Pamphlet
Many people with chronic kidney disease (CKD) have anemia (not enough red blood cells or hemoglobin in the blood). Taking oral irons will give you enough iron to make hemoglobin. The pamphlet explains what oral irons are, how to take and store them, and possible side effects.
Available Online
View Pamphlet
Corporate Author
Nova Scotia Health Authority. Renal Program
Alternate Title
Oral irons and CKD
Place of Publication
Halifax, NS
Publisher
Nova Scotia Health Authority
Date of Publication
2023
Format
Pamphlet
Language
English
Physical Description
1 electronic document ([4] p.) : digital, PDF file
Subjects (MeSH)
Renal insufficiency, chronic - complications
Renal Insufficiency, Chronic - drug therapy
Anemia, Iron-Deficiency - drug therapy
Subjects (LCSH)
Chronic renal failure--Complications
Iron deficiency anemia
Renal pharmacology
Abstract
Many people with chronic kidney disease (CKD) have anemia (not enough red blood cells or hemoglobin in the blood). Taking oral irons will give you enough iron to make hemoglobin. The pamphlet explains what oral irons are, how to take and store them, and possible side effects.
Responsibility
Prepared by: Renal Program
Pamphlet Number
1469
Less detail

Over-the-counter medications and chronic kidney disease (CKD)

https://libcat.nshealth.ca/en/permalink/chpams35643
Nova Scotia Health Authority. Renal Program. Halifax, NS: Nova Scotia Health Authority , 2023.
Pamphlet Number
1636
Available Online
View Pamphlet
If you have chronic kidney disease (CKD), you need to know which over-the-counter medications are your best choices and which you should not take. This pamphlet lists over-the-counter medications you may need for a cough or cold, fever or pain, allergies, an upset stomach (indigestion, burning pain) or heartburn, nausea (feeling sick to your stomach) or vomiting (throwing up), diarrhea (loose, watery poop), and constipation, as well as multivitamins, and creams and ointments. Information on why…
Available Online
View Pamphlet
Corporate Author
Nova Scotia Health Authority. Renal Program
Place of Publication
Halifax, NS
Publisher
Nova Scotia Health Authority
Date of Publication
2023
Format
Pamphlet
Language
English
Physical Description
1 electronic document (9 p.) : digital, PDF file
Subjects (MeSH)
Nonprescription Drugs
Renal Insufficiency, Chronic - drug therapy
Subjects (LCSH)
Drugs, Nonprescription
Chronic renal failure
Abstract
If you have chronic kidney disease (CKD), you need to know which over-the-counter medications are your best choices and which you should not take. This pamphlet lists over-the-counter medications you may need for a cough or cold, fever or pain, allergies, an upset stomach (indigestion, burning pain) or heartburn, nausea (feeling sick to your stomach) or vomiting (throwing up), diarrhea (loose, watery poop), and constipation, as well as multivitamins, and creams and ointments. Information on why you should not take any herbal or natural health products is included.
Notes
Previous title: Over-the-counter medications & chronic kidney disease
Responsibility
Prepared by: Renal Program
Pamphlet Number
1636
Less detail

Bowel preparation for chronic kidney disease before colonoscopy

https://libcat.nshealth.ca/en/permalink/chpams35387
Nova Scotia Health Authority. Renal Program, Nova Scotia Health Authority. Pharmacy Services. Halifax, NS: Nova Scotia Health Authority , 2020.
Pamphlet Number
1475
Available Online
View Pamphlet
This pamphlet describes how to get ready for a colonoscopy if you have chronic kidney disease. Steps to prepare solutions on the day before your colonoscopy are listed. The day before your procedure and on the day of the test you should drink only clear liquids, and a suggested list is included. Remember not to eat any food or drink milk, or other liquids that are not clear, on the day before your colonoscopy or on the day of the test.
Available Online
View Pamphlet
Corporate Author
Nova Scotia Health Authority. Renal Program
Nova Scotia Health Authority. Pharmacy Services
Place of Publication
Halifax, NS
Publisher
Nova Scotia Health Authority
Date of Publication
2020
Format
Pamphlet
Language
English
Physical Description
1 electronic document (5 p.) : digital, PDF file
Subjects (MeSH)
Cathartics
Colonoscopy
Renal Insufficiency, Chronic
Subjects (LCSH)
Laxatives
Colonoscopy
Chronic renal failure
Specialty
Medications
Nephrology
Abstract
This pamphlet describes how to get ready for a colonoscopy if you have chronic kidney disease. Steps to prepare solutions on the day before your colonoscopy are listed. The day before your procedure and on the day of the test you should drink only clear liquids, and a suggested list is included. Remember not to eat any food or drink milk, or other liquids that are not clear, on the day before your colonoscopy or on the day of the test.
Responsibility
Prepared by: NSHA Renal Program Educators and Pharmacists
Pamphlet Number
1475
Less detail

Taking your medicines when you are sick: a guide for patients with chronic kidney disease (CKD)

https://libcat.nshealth.ca/en/permalink/chpams36519
Nova Scotia Health Authority. NSHA Renal Program. Halifax, NS: Nova Scotia Health Authority , 2019.
Pamphlet Number
1340
Available Online
View Pamphlet
This pamphlet lists medications to avoid when you are sick while managing chronic kidney disease. The pamphlet includes instructions for what to do if you are throwing up or have diarrhea, what to do if you are diabetic, as well as what to do if you are unsure whether to take a certain medication. It also gives a page for writing a sick day plan.
Available Online
View Pamphlet
Corporate Author
Nova Scotia Health Authority. NSHA Renal Program
Place of Publication
Halifax, NS
Publisher
Nova Scotia Health Authority
Date of Publication
2019
Format
Pamphlet
Language
English
Physical Description
1 electronic document (5 p.) : digital, PDF file
Subjects (MeSH)
Kidney Diseases - drug therapy
Renal Insufficiency, Chronic - drug therapy
Subjects (LCSH)
Chronic renal failure
Kidneys--Diseases
Abstract
This pamphlet lists medications to avoid when you are sick while managing chronic kidney disease. The pamphlet includes instructions for what to do if you are throwing up or have diarrhea, what to do if you are diabetic, as well as what to do if you are unsure whether to take a certain medication. It also gives a page for writing a sick day plan.
Notes
Previous title: Taking your Medicines when you are Ill - A Guide for Patients with Chronic Kidney Disease
Responsibility
Prepared by: NSHA Renal Program
Pamphlet Number
1340
Less detail

Acute hemodialysis

https://libcat.nshealth.ca/en/permalink/chpams35036
Nova Scotia Health Authority. QEII. Nephrology Services. Halifax, NS: Nova Scotia Health Authority , 2023.
Pamphlet Number
1151
Available Online
View Pamphlet
Hemodialysis is a treatment that uses a machine to filter your blood and remove waste and extra water from your blood. Topics include: what your kidneys do, what acute kidney failure is, what peritoneal dialysis is, what hemodialysis is, and how to live with kidney disease. A resource list is also given.
Available Online
View Pamphlet
Corporate Author
Nova Scotia Health Authority. QEII. Nephrology Services
Place of Publication
Halifax, NS
Publisher
Nova Scotia Health Authority
Date of Publication
2023
Format
Pamphlet
Language
English
Physical Description
1 electronic document (8 p.) : digital, PDF file
Subjects (MeSH)
Renal Dialysis
Acute Kidney Injury
Kidney Diseases - therapy
Subjects (LCSH)
Hemodialysis
Acute renal failure
Abstract
Hemodialysis is a treatment that uses a machine to filter your blood and remove waste and extra water from your blood. Topics include: what your kidneys do, what acute kidney failure is, what peritoneal dialysis is, what hemodialysis is, and how to live with kidney disease. A resource list is also given.
Responsibility
Prepared by: Nephrology Services
Pamphlet Number
1151
Less detail

Erythropoieis-stimulating agents (ESAs) for chronic kidney disease (CKD) : with active cancer or a history of cancer or stroke

https://libcat.nshealth.ca/en/permalink/chpams37446
Nova Scotia Health Authority. Renal Program. Halifax, NS: Nova Scotia Health Authority , 2021.
Pamphlet Number
2217
Available Online
View Pamphlet
Erythropoiesis-stimulating agents (ESAs) are a group of medicines that help take the place of a hormone called erythropoietin (EPO). People with chronic kidney disease (CKD) may not have enough EPO coming from their kidneys to tell their body to make more red blood cells. This can cause their red blood cell count to drop and anemia (not enough red blood cells or hemoglobin in the blood) to develop. If you have CKD and active cancer or a history of cancer of stroke, it is important to carefully …
Available Online
View Pamphlet
Corporate Author
Nova Scotia Health Authority. Renal Program
Place of Publication
Halifax, NS
Publisher
Nova Scotia Health Authority
Date of Publication
2021
Format
Pamphlet
Language
English
Physical Description
1 electronic document ([2] p.) : digital, PDF file
Subjects (MeSH)
Renal insufficiency, chronic - complications
Anemia - drug therapy
Hematinics - therapeutic use
Neoplasms
Stroke
Subjects (LCSH)
Chronic renal failure--Complications
Hematopoietic growth factors
Renal anemia--Chemotherapy
Cancer
Cerebrovascular disease
Abstract
Erythropoiesis-stimulating agents (ESAs) are a group of medicines that help take the place of a hormone called erythropoietin (EPO). People with chronic kidney disease (CKD) may not have enough EPO coming from their kidneys to tell their body to make more red blood cells. This can cause their red blood cell count to drop and anemia (not enough red blood cells or hemoglobin in the blood) to develop. If you have CKD and active cancer or a history of cancer of stroke, it is important to carefully consider the risks and benefits of ESAs. The risks and benefits of ESAs are listed. Your health care team will talk with you about the risks and benefits of ESAs and other factors to consider when making the decision to take ESAs.
Responsibility
Prepared by: Renal Program
Pamphlet Number
2217
Less detail

Cinacalcet (Sensipar) for secondary hyperparathyroidism in chronic kidney disease (CKD)

https://libcat.nshealth.ca/en/permalink/chpams35371
Nova Scotia Health Authority. Renal Program. Halifax, NS: Nova Scotia Health Authority , 2023.
Pamphlet Number
1465
Available Online
View Pamphlet
Secondary hyperparathyroidism is a condition that can be caused by chronic kidney disease (CKD). It happens when your kidneys cannot filter out waste products the right way. This leads to too much parathyroid hormone in your blood. Cinacalcet (sin-a-KAL-cet) is a medication that lowers the amount of parathyroid hormone in your blood. This will help to balance the amount of calcium and phosphorous in your blood. Sensipar® is the brand name for cinacalcet. This pamphlet explains how to take cinac…
Available Online
View Pamphlet
Corporate Author
Nova Scotia Health Authority. Renal Program
Place of Publication
Halifax, NS
Publisher
Nova Scotia Health Authority
Date of Publication
2023
Format
Pamphlet
Language
English
Physical Description
1 electronic document ([4] p.) : digital, PDF file
Subjects (MeSH)
Cinacalcet
Renal Insufficiency, Chronic - drug therapy
Hyperparathyroidism, Secondary - drug therapy
Subjects (LCSH)
Chronic renal failure
Hyperparathyroidism
Kidneys--Diseases--Treatment
Abstract
Secondary hyperparathyroidism is a condition that can be caused by chronic kidney disease (CKD). It happens when your kidneys cannot filter out waste products the right way. This leads to too much parathyroid hormone in your blood. Cinacalcet (sin-a-KAL-cet) is a medication that lowers the amount of parathyroid hormone in your blood. This will help to balance the amount of calcium and phosphorous in your blood. Sensipar® is the brand name for cinacalcet. This pamphlet explains how to take cinacalcet, possible side effects, and how to store this medication.
Notes
Previous title: Sensipar (Cinacalcet) to treat secondary hyperparathyroidism in chronic kidney disease
Previous title: Cinacalcet (Sensipar) to treat secondary hyperparathyroidism in chronic kidney disease (CKD)
Responsibility
Prepared by: Renal Program
Pamphlet Number
1465
Less detail

Dalteparin (Fragmin) to prevent clotting during hemodialysis

https://libcat.nshealth.ca/en/permalink/chpams35807
Nova Scotia Health Authority. Renal Program. Halifax, NS: Nova Scotia Health Authority , 2020.
Pamphlet Number
1760
Available Online
View Pamphlet
Dalteparin is a medication that is part of a group of drugs called blood thinners. Fragmin® is the brand name of dalteparin. During hemodialysis your blood passes through the dialysis blood lines and a dialyzer (artificial kidney), which can cause clots to form. Dalteparin stops clots from forming. This pamphlet explains how to take dalteparin, possible side effects, and symptoms that you should mention to your nurse.
Available Online
View Pamphlet
Corporate Author
Nova Scotia Health Authority. Renal Program
Place of Publication
Halifax, NS
Publisher
Nova Scotia Health Authority
Date of Publication
2020
Format
Pamphlet
Language
English
Physical Description
1 electronic document ([4] p.) : digital, PDF file
Subjects (MeSH)
Dalteparin
Renal Dialysis
Subjects (LCSH)
Hemodialysis
Blood--coagulation
Specialty
Nephrology
Abstract
Dalteparin is a medication that is part of a group of drugs called blood thinners. Fragmin® is the brand name of dalteparin. During hemodialysis your blood passes through the dialysis blood lines and a dialyzer (artificial kidney), which can cause clots to form. Dalteparin stops clots from forming. This pamphlet explains how to take dalteparin, possible side effects, and symptoms that you should mention to your nurse.
Responsibility
Prepared by: Renal Program
Pamphlet Number
1760
Less detail

Care of your arteriovenous fistula

https://libcat.nshealth.ca/en/permalink/chpams35622
Nova Scotia Health Authority. Renal Program. Halifax, NS: Nova Scotia Health Authority , 2022.
Pamphlet Number
0651
Available Online
View Pamphlet
An arteriovenous (AV) fistula gives access to your bloodstream for hemodialysis. It is made by joining an artery and a vein during surgery. This pamphlet explains when your fistula will be ready to use, what to expect after your surgery, how to care for your incision (cut), and how to exercise your fistula arm before and after surgery. It also includes information about what to do if you have bleeding at your fistula site, and a list of symptoms that need medical attention right away.
Available Online
View Pamphlet
Corporate Author
Nova Scotia Health Authority. Renal Program
Place of Publication
Halifax, NS
Publisher
Nova Scotia Health Authority
Date of Publication
2022
Format
Pamphlet
Language
English
Physical Description
1 electronic document (9 p.) : digital, PDF file
Subjects (MeSH)
Central Venous Catheters
Renal Dialysis
Subjects (LCSH)
Hemodialysis
Specialty
Nephrology
Abstract
An arteriovenous (AV) fistula gives access to your bloodstream for hemodialysis. It is made by joining an artery and a vein during surgery. This pamphlet explains when your fistula will be ready to use, what to expect after your surgery, how to care for your incision (cut), and how to exercise your fistula arm before and after surgery. It also includes information about what to do if you have bleeding at your fistula site, and a list of symptoms that need medical attention right away.
Responsibility
Prepared by: Renal Program
Pamphlet Number
0651
Less detail

Injectable iron and chronic kidney disease (CKD)

https://libcat.nshealth.ca/en/permalink/chpams35408
Nova Scotia Health Authority. Renal Program. Halifax, NS: Nova Scotia Health Authority , 2023.
Pamphlet Number
1495
Available Online
View Pamphlet
Many people with chronic kidney disease (CKD), or who are on dialysis, have anemia because their red blood cells are low. The body needs iron to help make new red blood cells. This pamphlet explains how to take and store this medication, and lists possible side effects. The French version of this pamphlet 2161, "Fer injectable et insuffisance rénale chronique (IRC)," is also available.
Available Online
View Pamphlet
Corporate Author
Nova Scotia Health Authority. Renal Program
Place of Publication
Halifax, NS
Publisher
Nova Scotia Health Authority
Date of Publication
2023
Format
Pamphlet
Language
English
Physical Description
1 electronic document ([4] p.) : digital, PDF file
Subjects (MeSH)
Renal Dialysis
Iron - therapeutic use
Kidney Diseases
Anemia, Iron-Deficiency
Subjects (LCSH)
Hemodialysis
Chronic renal failure--Complications
Iron deficiency anemia
Abstract
Many people with chronic kidney disease (CKD), or who are on dialysis, have anemia because their red blood cells are low. The body needs iron to help make new red blood cells. This pamphlet explains how to take and store this medication, and lists possible side effects. The French version of this pamphlet 2161, "Fer injectable et insuffisance rénale chronique (IRC)," is also available.
Notes
Previous title: Injectable iron sucrose and chronic kidney disease
Responsibility
Prepared by: Renal Program
Pamphlet Number
1495
Less detail

Fer injectable et insuffisance rénale chronique (IRC)

https://libcat.nshealth.ca/en/permalink/chpams37473
Nova Scotia Health Authority. Renal Program. Halifax, NS: Nova Scotia Health Authority , 2020.
Pamphlet Number
2161
Available Online
View Pamphlet
Si votre corps manque d’oxygène en raison d’une carence en fer, il se peut que vous soyez fatigué ou essoufflé. On appelle cela l’anémie ferriprive. Beaucoup de patients atteints d’insuffisance rénale chronique (IRC) ou dialysés souffrent d’anémie, car ils n’ont pas assez de globules rouges, et le corps a besoin de fer pour les fabriquer. Prendre du fer par injection permet donc au corps d’avoir suffisamment de fer pour fabriquer de l’hémoglobine, c’est-à-dire la protéine qui transporte l’oxygè…
Available Online
View Pamphlet
Corporate Author
Nova Scotia Health Authority. Renal Program
Alternate Title
Injectable iron and chronic kidney disease (CKD)
Place of Publication
Halifax, NS
Publisher
Nova Scotia Health Authority
Date of Publication
2020
Format
Pamphlet
Language
French
Physical Description
1 electronic document ([4] p.) : digital, PDF file
Subjects (MeSH)
Renal Dialysis
Iron - therapeutic use
Kidney Diseases
Anemia, Iron-Deficiency
Subjects (LCSH)
Hemodialysis
Chronic renal failure--Complications
Iron deficiency anemia
Abstract
Si votre corps manque d’oxygène en raison d’une carence en fer, il se peut que vous soyez fatigué ou essoufflé. On appelle cela l’anémie ferriprive. Beaucoup de patients atteints d’insuffisance rénale chronique (IRC) ou dialysés souffrent d’anémie, car ils n’ont pas assez de globules rouges, et le corps a besoin de fer pour les fabriquer. Prendre du fer par injection permet donc au corps d’avoir suffisamment de fer pour fabriquer de l’hémoglobine, c’est-à-dire la protéine qui transporte l’oxygène. Ce dépliant explique comment prendre du fer injectable, ses effets possibles et comment le conserver.
This pamphlet is a French translation of the English pamphlet 1495, "Injectable Iron and Chronic Kidney Disease (CKD)". If your body is not getting enough oxygen due to lack of iron, you may feel tired or short of breath. This is called iron deficiency anemia. Many patients with chronic kidney disease (CKD), or who are on dialysis, have anemia because their red blood cells are low. The body needs iron to help make new red blood cells. Getting iron injections can help make sure that you have enough iron in your body to make the oxygen-carrying part (hemoglobin) of your red blood cells. This pamphlet explains how to take injectable iron, side effects to watch for, and instructions on how to store the medication.
Notes
Previous title: Injectable iron sucrose and chronic kidney disease
Responsibility
Prepared by: NSHA Renal Program
Pamphlet Number
2161
Less detail

Tunneled hemodialysis catheter

https://libcat.nshealth.ca/en/permalink/chpams35616
Nova Scotia Health Authority. Renal Program. Halifax, NS: Nova Scotia Health Authority , 2022.
Pamphlet Number
1032
Available Online
View Pamphlet
A tunneled hemodialysis catheter is a special tube made of plastic. It is used for hemodialysis treatment. This pamphlet explains the procedure for having a tunneled hemodialysis catheter inserted. Topics include: why the catheter is used, how long it will be in place, where the procedure is done, how long you will be at the hospital, how to get ready, and how the catheter is inserted. Instructions for after your procedure and care at home are provided.
Available Online
View Pamphlet
Corporate Author
Nova Scotia Health Authority. Renal Program
Place of Publication
Halifax, NS
Publisher
Nova Scotia Health Authority
Date of Publication
2022
Format
Pamphlet
Language
English
Physical Description
1 electronic document (9 p.) : digital, PDF file
Subjects (MeSH)
Renal Dialysis
Vascular Access Devices
Subjects (LCSH)
Hemodialysis
Catheters
Specialty
Nephrology
Abstract
A tunneled hemodialysis catheter is a special tube made of plastic. It is used for hemodialysis treatment. This pamphlet explains the procedure for having a tunneled hemodialysis catheter inserted. Topics include: why the catheter is used, how long it will be in place, where the procedure is done, how long you will be at the hospital, how to get ready, and how the catheter is inserted. Instructions for after your procedure and care at home are provided.
Responsibility
Prepared by: Renal Program
Pamphlet Number
1032
Less detail

Non-tunneled hemodialysis catheter

https://libcat.nshealth.ca/en/permalink/chpams35618
Nova Scotia Health Authority. Renal Program. Halifax, NS: Nova Scotia Health Authority , 2022.
Pamphlet Number
1093
Available Online
View Pamphlet
A non-tunneled hemodialysis catheter is a special tube made of plastic. It is used for hemodialyis treatment. This pamphlet explains the procedure for having a non-tunneled hemodialysis cathether inserted. Topics include: why the catheter is used, how long it can stay in place, how it is inserted, what will happen after the procedure, and how to care for your catheter at home. The pamphlet also explains what to do if the catheter falls out.
Available Online
View Pamphlet
Corporate Author
Nova Scotia Health Authority. Renal Program
Place of Publication
Halifax, NS
Publisher
Nova Scotia Health Authority
Date of Publication
2022
Format
Pamphlet
Language
English
Physical Description
1 electronic document (5 p.) : digital, PDF file
Subjects (MeSH)
Renal Dialysis
Vascular Access Devices
Subjects (LCSH)
Catheters
Hemodialysis
Specialty
Nephrology
Abstract
A non-tunneled hemodialysis catheter is a special tube made of plastic. It is used for hemodialyis treatment. This pamphlet explains the procedure for having a non-tunneled hemodialysis cathether inserted. Topics include: why the catheter is used, how long it can stay in place, how it is inserted, what will happen after the procedure, and how to care for your catheter at home. The pamphlet also explains what to do if the catheter falls out.
Responsibility
Prepared by: Renal Program
Pamphlet Number
1093
Less detail

In-centre hemodialysis

https://libcat.nshealth.ca/en/permalink/chpams35162
Nova Scotia Health Authority. Central Zone. Renal Program. Halifax, NS: Nova Scotia Health Authority , 2023.
Pamphlet Number
1220
Available Online
View Pamphlet
This pamphlet is for patients who are beginning dialysis. It explains what to expect when starting hemodialysis, common questions you may have, your hemodialysis schedule, and your hemodialysis health care team. Information about Patient Rights and Responsibilities, Patient Relations, and Ethics is included. The pamphlet also includes a list of resources and words you may hear during your treatment. A blank Hemodialysis Care Plan, Hemodialysis Tracking Sheet, and Hemodialysis checklist are also…
Available Online
View Pamphlet
Corporate Author
Nova Scotia Health Authority. Central Zone. Renal Program
Alternate Title
In centre hemodialysis
Place of Publication
Halifax, NS
Publisher
Nova Scotia Health Authority
Date of Publication
2023
Format
Pamphlet
Language
English
Physical Description
1 electronic document (24 p.) : digital, PDF file
Subjects (MeSH)
Renal Dialysis
Kidney Diseases - therapy
Subjects (LCSH)
Hemodialysis
Kidneys--Diseases
Specialty
Nephrology
Abstract
This pamphlet is for patients who are beginning dialysis. It explains what to expect when starting hemodialysis, common questions you may have, your hemodialysis schedule, and your hemodialysis health care team. Information about Patient Rights and Responsibilities, Patient Relations, and Ethics is included. The pamphlet also includes a list of resources and words you may hear during your treatment. A blank Hemodialysis Care Plan, Hemodialysis Tracking Sheet, and Hemodialysis checklist are also included.
Notes
Previous titles: Renal (dialysis) patient handbook, Hemodialysis patient handbook
Responsibility
Prepared by: Renal Program, Central Zone
Pamphlet Number
1220
Less detail

Treatment of high potassium with Kayexalate powder in hemodialysis patients

https://libcat.nshealth.ca/en/permalink/chpams35337
Nova Scotia Health Authority. Renal Program. Halifax, NS: Nova Scotia Health Authority , 2021.
Pamphlet Number
1445
Available Online
View Pamphlet
People with kidney disease have a higher chance of having high potassium levels. High potassium levels may lead to an irregular heartbeat or cause problems with muscles and nerves. Kayexalate® is a drug that treats high potassium levels. This pamphlet explains how to take Kayexlate®, side effects, and how to store this medication.
Available Online
View Pamphlet
Corporate Author
Nova Scotia Health Authority. Renal Program
Place of Publication
Halifax, NS
Publisher
Nova Scotia Health Authority
Date of Publication
2021
Format
Pamphlet
Language
English
Physical Description
1 electronic document ([4] p.) : digital, PDF file
Subjects (MeSH)
Renal Dialysis
Polystyrene sulfonic acid
Hyperkalemia
Subjects (LCSH)
Drugs
Low-potassium diet
Specialty
Nephrology
Medications
Abstract
People with kidney disease have a higher chance of having high potassium levels. High potassium levels may lead to an irregular heartbeat or cause problems with muscles and nerves. Kayexalate® is a drug that treats high potassium levels. This pamphlet explains how to take Kayexlate®, side effects, and how to store this medication.
Responsibility
Prepared by: Renal Program
Pamphlet Number
1445
Less detail

45 records – page 1 of 3.